Literature DB >> 18804512

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.

Naghmeh Khoshgoo1, Farnaz Zahedifard, Hiva Azizi, Yasaman Taslimi, Maribel Jiménez Alonso, Sima Rafati.   

Abstract

Visceral leishmaniasis is the most acute form of leishmaniasis and vaccination is the best approach to control it. One of the major groups of virulence factors in Leishmania belongs to cysteine proteinase family. In this study, for the first time, the protective potential of Leishmania infantum cysteine proteinase type III (CPC) by using a prime-boost strategy is evaluated in BALB/c mice. The experiment was carried out in three groups of mice. Vaccinated group was primed with pcDNA-cpc and boosted with rCPC-DHFR in combination with CpG motif and Montanide 720 as adjuvant. Control groups received pcDNA and rDHFR or PBS. The ratio of IgG2a/IgG1, nitric oxide concentration and IFN-gamma induction in vaccinated group is significantly higher than controls. Furthermore, the parasite load of vaccinated group is significantly lower than controls. In addition, sera reactivity of visceral leishmaniasis individuals was examined and showed considerable reactivities toward rCPC in comparison with cutaneous leishmaniasis. The achieved result is highly encouraging the use of cysteine proteinases types I, II and III as vaccine candidate against visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18804512     DOI: 10.1016/j.vaccine.2008.08.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine.

Authors:  Narges Khabazzadeh Tehrani; Mehdi Mahdavi; Fatemeh Maleki; Somayeh Zarrati; Fatemeh Tabatabaie
Journal:  J Parasit Dis       Date:  2014-09-20

Review 2.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

3.  Cloning of a Recombinant Plasmid Encoding Thiol-Specific Antioxidant Antigen (TSA) Gene of Leishmania majorand Expression in the Chinese Hamster Ovary Cell Line.

Authors:  Ghaffarifar Fatemeh; Tabatabaie Fatemeh; Sharifi Zohreh; Dalimiasl Abdolhosein; Hassan Mohammad Zahir; Mahdavi Mehdi
Journal:  Malays J Med Sci       Date:  2012-01

4.  Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis.

Authors:  Toolika Singh; Michaela Fakiola; Joyce Oommen; Akhil Pratap Singh; Abhishek K Singh; Noel Smith; Jaya Chakravarty; Shyam Sundar; Jenefer M Blackwell
Journal:  J Immunol       Date:  2018-03-05       Impact factor: 5.422

5.  Old World cutaneous leishmaniasis: diagnosis and treatment.

Authors:  Abderrahmen Masmoudi; Wala Hariz; Slaheddine Marrekchi; Mariem Amouri; Hamida Turki
Journal:  J Dermatol Case Rep       Date:  2013-06-30

6.  Optimized subunit vaccine protects against experimental leishmaniasis.

Authors:  Sylvie Bertholet; Yasuyuki Goto; Lauren Carter; Ajay Bhatia; Randall F Howard; Darrick Carter; Rhea N Coler; Thomas S Vedvick; Steven G Reed
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

7.  Cellular and humoral responses to Leishmania major virulence factors in healed cutaneous leishmaniasis and Mediterranean visceral leishmaniasis patients.

Authors:  Inès Lakhal-Naouar; Thouraya Boussoffara; Amel Meddeb-Garnaoui; Yosser Ben Achour-Chenik; Hechmi Louzir; Mehdi Chenik
Journal:  Clin Vaccine Immunol       Date:  2009-04-01

8.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

9.  Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis.

Authors:  Pramod Kumar Kushawaha; Reema Gupta; Chandra Dev Pati Tripathi; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

10.  Combining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protection.

Authors:  Amrita Das; Nahid Ali
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.